America Great Health
AAGHdata completeness 88%14 fiscal years on fileData notes: no data for concept 'investmentsAtFairValue'; no data for concept 'netInvestmentIncome'; no data for concept 'gainsOnRealEstateSales'; no data for concept 'realEstateImpairment'; no data for concept 'dividendsPaid'
| Figure | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|
| Revenue | $195,6711 | $104,6482 | $204,3083 | $294,6704 | $391,7434 |
| Net income | −$269,0545 | −$4.92M6 | −$761,4207 | −$1.22M8 | −$719,1198 |
| Operating cash flow | −$329,2419 | −$1.48M10 | −$389,80911 | −$615,62712 | −$332,86212 |
| Capital expenditure | $12,67113 | $16,85114 | $44,42015 | $015 | — |
| Free cash flow (derived) | −$341,9129 | −$1.5M10 | −$434,22911 | −$615,62712 | — |
| Total debt | $1.16M16 | $2.44M17 | $3.78M18 | $4.27M19 | $5.04M19 |
| Cash & equivalents | $396,13620 | $62,64321 | $54,15022 | $54,94322 | $44,05622 |
| Diluted shares | 21.07B | 21.09B | 21.09B | 21.12B | 21.14B |
Superscripts are receipts. Each links to the SEC filing the number came from (full list at the bottom).
10 shares is a claim on −$0 of net worth that earned you −$0 last year, against $0 of debt.
Not enough data in the filings for a return-on-capital reading.
seeing a moat in the numbers →Share count is roughly flat over 5 years — little dilution, little buyback. Total debt has risen 333% over the same window.
reading capital allocation →Signals, not verdicts — read from the filings above. Numbers don’t prove a moat; they show its footprint. You decide.
Different models answer different questions — which to trust when →
- 10-K · period ending 2021-06-30 · accession 0001185185-22-001238 (Revenues)
- 10-K/A · period ending 2022-06-30 · accession 0001185185-24-000144 (Revenues)
- 10-K · period ending 2023-06-30 · accession 0001185185-25-000157 (Revenues)
- 10-K · period ending 2024-06-30 · accession 0001185185-26-001339 (Revenues)
- 10-K · period ending 2021-06-30 · accession 0001185185-22-001238 (NetIncomeLoss)
- 10-K/A · period ending 2022-06-30 · accession 0001185185-24-000144 (NetIncomeLoss)
- 10-K · period ending 2023-06-30 · accession 0001185185-25-000157 (NetIncomeLoss)
- 10-K · period ending 2024-06-30 · accession 0001185185-26-001339 (NetIncomeLoss)
- 10-K · period ending 2021-06-30 · accession 0001185185-22-001238 (NetCashProvidedByUsedInOperatingActivities)
- 10-K/A · period ending 2022-06-30 · accession 0001185185-24-000144 (NetCashProvidedByUsedInOperatingActivities)
- 10-K · period ending 2023-06-30 · accession 0001185185-25-000157 (NetCashProvidedByUsedInOperatingActivities)
- 10-K · period ending 2024-06-30 · accession 0001185185-26-001339 (NetCashProvidedByUsedInOperatingActivities)
- 10-K · period ending 2021-06-30 · accession 0001185185-22-001238 (PaymentsToAcquirePropertyPlantAndEquipment)
- 10-K/A · period ending 2022-06-30 · accession 0001185185-24-000144 (PaymentsToAcquirePropertyPlantAndEquipment)
- 10-K · period ending 2023-06-30 · accession 0001185185-25-000157 (PaymentsToAcquirePropertyPlantAndEquipment)
- 10-K · period ending 2021-06-30 · accession 0001185185-22-001238 (LongTermDebtNoncurrent)
- 10-K/A · period ending 2022-06-30 · accession 0001185185-24-000144 (LongTermDebtNoncurrent)
- 10-K · period ending 2023-06-30 · accession 0001185185-25-000157 (LongTermDebtNoncurrent)
- 10-K · period ending 2024-06-30 · accession 0001185185-26-001339 (LongTermDebtNoncurrent)
- 10-K · period ending 2021-06-30 · accession 0001185185-22-000080 (CashAndCashEquivalentsAtCarryingValue)
- 10-K · period ending 2022-06-30 · accession 0001185185-25-000157 (CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents)
- 10-K · period ending 2023-06-30 · accession 0001185185-26-001339 (CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents)